Intersect ENT received CMS approval of a revised coding application for its Propel sinus implant, according to a Jan. 19 news release.
Propel previously shared a billing code with Intersect ENT's Sinuva implant, the release said. The new approval establishes a separate code for Propel and updates Sinuva's J-Code to J7402.
Propel products are the first and only bioabsorbable steroid-releasing sinus implants approved by the FDA to maintain patency and locally deliver steroids to adults after sinus surgery, the release said.